1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | Apixaban |
| brand | String | Eliquis |
| structure | File | |
| classes | List of String, delimiter: , | [[:Category:Anticoagulants|Anticoagulant]] • [[:Category:Direct_factor_Xa_inhibitors|Direct factor Xa inhibitor]] • [[:Category:DOACs|Direct oral anticoagulant (DOAC)]] |
| mechanism | String | '"`UNIQ--vote-000001F6-QINU`"' CYP3A4 (primary) and P-glycoprotein substrate; strong dual inhibitors or inducers materially shift exposure. Reversal: andexanet alfa for life-threatening bleeding; 4F-PCC commonly used off-label when andexanet unavailable'"`UNIQ--ref-000001F7-QINU`"'. |
| uses | String | '"`UNIQ--vote-000001F8-QINU`"', '"`UNIQ--vote-000001F9-QINU`"', '"`UNIQ--vote-000001FA-QINU`"' |
| starting_dose | String | NVAF: 5 mg PO BID (2.5 mg BID if 2 of 3: age ≥80, weight ≤60 kg, serum creatinine ≥1.5 mg/dL); acute VTE: 10 mg BID for 7 days, then 5 mg BID |
| preparations | String | 2.5 mg, 5 mg tablets |
| fda_max | String | 10 mg BID for the first 7 days of acute VTE; otherwise 5 mg BID |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral |
| onset | String | Peak anticoagulant effect 3-4 hours |
| duration | String | 12 hours |
| halflife | String | ~12 hours'"`UNIQ--ref-000001FB-QINU`"' |
| bioavailability | String | ~50% (oral; not significantly affected by food)'"`UNIQ--ref-000001FC-QINU`"' |
| pregnancy | String | |
| legal | String | [[USLegal:Prescription only|Rx-only]] in US |
